You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
HIV-1 DNA drug resistance testing to guide successful suppression of low-level viraemia: a case report
  1. Bianchuan Cao1,2,
  2. Mei Liu3,
  3. Rui Zhu3,
  4. Tianru Yuan3,
  5. A’shamu E’er3,
  6. Shaofang Song3,
  7. Tong Wang4,
  8. Li Zhong1,2
  1. 1 Department of Infectious Disease, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
  2. 2 Department of Tuberculosis, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
  3. 3 Antiviral Therapy Center, the First People’s Hospital of Yuexi County, Liangshan, Sichuan, China
  4. 4 MOE Key Laboratory of Tumor Molecular Biology, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University First Affiliated Hospital, Guangzhou, Guangdong, China
  1. Correspondence to Dr Li Zhong, Department of Infectious Disease, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China; zhongli620{at}163.com

https://doi.org/10.1136/sextrans-2023-055860

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A treatment-naïve 10-year-old female patient living with HIV-1 infection started antiretroviral therapy (ART) in April 2018 with zidovudine+lamivudine+nevirapine, which was changed 19 months later to zidovudine+lamivudine+efavirenz. The HIV-1 RNA load ranged between 55 and 420 copies/mL between February 2020 and May 2021, and was 485 copies/mL in January 2022. At this time, the total HIV-1 DNA load in peripheral blood was 2260 copies/million white blood cells (WBCs) as measured with a HIV-1 DNA quantification kit (Supbio, Guangzhou, China). Genotypic drug resistance testing (pol region amplification …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • TW and LZ contributed equally.

    • Correction notice Since this article was first published, the patient consent for publication section has been updated.

    • Contributors BC directed the clinical treatment, supervised the follow-up and wrote this case report. ML, RZ, TY, AE and SS contributed to the clinical treatment and follow-up. TW and LZ conceived the idea and contributed to the manuscript preparation of this case report.

    • Funding This work was supported by Chinese Association of STD & AIDS Prevention and Control·Maternal and Child Tigermed Care and Prevention of Maternal to Child Transmission Fund (PMTCT202207), the National Natural Science Foundation of China (81973353), and the Fund of Innovation and Entrepreneurship Leading Team Project of Guangzhou (201809010009).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.